ARCT
USDArcturus Therapeutics Holdings Inc. Common Stock
Real-time Price
Price Chart
Key Metrics
Market Metrics
Open
$9.170
High
$9.400
Low
$8.840
Volume
1.18M
Company Fundamentals
Market Cap
242.5M
Industry
Biotechnology
Country
United States
Trading Stats
Avg Volume
1.22M
Exchange
NGM
Currency
USD
52-Week Range
Related News
HC Wainwright & Co. Downgrades Arcturus Therapeutics to Neutral, Lowers Price Target to $12
HC Wainwright & Co. analyst Andrew S. Fein downgrades Arcturus Therapeutics from Buy to Neutral and lowers the price target from $60 to $12.
Citigroup Downgrades Arcturus Therapeutics to Neutral, Lowers Price Target to $12
Citigroup analyst Yigal Nochomovitz downgrades Arcturus Therapeutics from Buy to Neutral and lowers the price target from $49 to $12.
Arcturus' Investigational Inhaled Therapy Lacks Meaningful Lung Function Improvement, Analyst Notes Mixed Picture
Arcturus stock drops on interim Phase 2 results for ARCT-032, showing promising mucus reduction in cystic fibrosis patients but no initial FEV₁ improvement.
BTIG Maintains Buy on Arcturus Therapeutics, Lowers Price Target to $23
BTIG analyst Thomas Shrader maintains Arcturus Therapeutics with a Buy and lowers the price target from $48 to $23.
Guggenheim Downgrades Arcturus Therapeutics to Neutral
Guggenheim analyst Seamus Fernandez downgrades Arcturus Therapeutics from Buy to Neutral.
Arcturus Therapeutics Provides Interim Phase 2 Data for Cystic Fibrosis (CF) Program
ARCT-032 generally safe and well tolerated Meaningful trends of clinical activity observed via high resolution CT scans After only 28 days of treatment with ARCT-032 (10 mg), 4 out of 6 Class I CF participants
Related Stocks
VRCA
Verrica Pharmaceuticals Inc.
XTLB
XTL Biopharmaceuticals Ltd. American Depositary Shares
SHLT
SHL Telemedicine Ltd American Depositary Shares
CMPX
Compass Therapeutics Inc.
APLMW
Apollomics Inc. Warrant
Stay Updated
Set price alerts, get AI analysis updates and real-time market news.